| Chapter title |
MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy.
|
|---|---|
| Chapter number | 3 |
| Book title |
Gene Therapy of Solid Cancers
|
| Published in |
Methods in molecular biology, January 2015
|
| DOI | 10.1007/978-1-4939-2727-2_3 |
| Pubmed ID | |
| Book ISBNs |
978-1-4939-2726-5, 978-1-4939-2727-2
|
| Authors |
Schmidt, Manuel, Volz, Barbara, Großmann, Patrick, Heinrich, Kerstin, Wittig, Burghardt, Manuel Schmidt, Barbara Volz, Patrick Großmann, Kerstin Heinrich, Burghardt Wittig |
| Abstract |
Gene modification of eukaryotic cells by electroporation is a widely used method to express selected genes in a defined cell population for various purposes, like gene correction or production of therapeutics. Here, we describe the generation of a cell-based tumor vaccine via fourfold transient gene modification of a human renal cell carcinoma (RCC) cell line for high expression of CD80, CD154, GM-CSF, and IL-7 by use of MIDGE(®) vectors. The two co-stimulatory molecules CD80 and CD154 are expressed at the cell surface, whereas the two cytokines GM-CSF and IL-7 are secreted yielding cells with enhanced immunological properties. These fourfold gene-modified cells have been used as a cell-based tumor vaccine for the treatment of RCC. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 2 | 40% |
| Student > Ph. D. Student | 1 | 20% |
| Student > Bachelor | 1 | 20% |
| Student > Postgraduate | 1 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 3 | 60% |
| Medicine and Dentistry | 1 | 20% |
| Engineering | 1 | 20% |